Clinical research treating mental illness with psychedelics has been happening for decades, but now there's a group of companies exclusively focused on using LSD and other psychedelics to treat mental health disorders.
Axios Re:Cap digs into the argument for legalizing prescription psychedelics, and the treacherous FDA approval path, with MindMed CEO JR Rahn, whose company recently listed on the Nasdaq.
